



Experience
INDIAN
HEALTHCARE

Poly Medicure Ltd.

POLYMED
Medical Devices

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA
Tel : +91-11-47317000, 33550700, 26321838 / 81 / 89 / 93 / 99, Fax : +91-11-26321894, 26321839
E-mail : info@polymedicure.com Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

Date: 29th October, 2018

Scrip Code: - 531768

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company
Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 29th October, 2018, at Crowne Plaza Hotels, Community Center, Okhla Phase-I, New Delhi - 110020, approved the following businesses:


- Un-Audited Financial Results (Standalone) for the quarter and half year ended on 30th September, 2018.
- Other normal business.

We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You,

Yours Sincerely

For Poly Medicure Limited


Avinash Chandra
Company Secretary





POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020

Phone: 011-26321889, Fax: 011-26321894

Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2018


		Quarter Ended			Half Year Ended		Year Ended
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
		(Unaudited)					(Audited)
(Rs. In Lacs)							
1	Income						
a	Revenue from Operations	14,675.06	13,136.74	13,492.57	27,811.80	24,359.02	50,969.93
b	Other income	410.60	333.27	251.63	743.87	616.34	1,436.95
	Total Income	15,085.66	13,470.01	13,744.20	28,555.67	24,975.36	52,406.88
2	Expenses						
a	Cost of materials consumed	4,535.73	4,255.20	4,147.14	8,790.93	7,933.51	16,713.93
b	Purchases of stock-in-trade	511.49	16.63	60.70	528.12	174.11	437.26
c	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(395.23)	(298.01)	113.66	(693.24)	(597.03)	(994.00)
d	Excise Duty on Sales	-	-	-	-	126.10	126.10
e	Employee benefits expense	2,677.34	2,602.30	2,373.02	5,279.64	4,490.75	9,392.66
f	Research and development expenses	304.73	293.34	249.37	598.07	494.06	1,004.78
g	Finance cost	643.91	381.02	240.93	1,024.93	451.57	949.51
h	Depreciation and amortisation expense	909.14	859.64	692.33	1,768.78	1,346.01	2,840.66
i	Other expenses	3,590.46	3,138.35	3,128.65	6,728.81	6,002.10	12,300.39
	Total expenses	12,777.57	11,248.47	11,005.80	24,026.04	20,421.18	42,771.29
3	Profit from operations before exceptional items (1-2)	2,308.09	2,221.54	2,738.40	4,529.63	4,554.18	9,635.59
4	Exceptional Items						
5	Profit before tax	2,308.09	2,221.54	2,738.40	4,529.63	4,554.18	9,635.59
6	Tax expense						
a	Current tax	753.44	695.78	905.35	1,449.22	1,573.36	2,536.55
b	Deferred tax	108.61	170.38	(25.50)	278.99	(79.89)	79.21
c	Earlier Year Taxes	-	(6.66)	-	(6.66)	-	-
	Total Tax Expense	862.05	859.50	879.85	1,721.55	1,493.47	2,615.76
7	Profit for the period	1,446.04	1,362.04	1,858.55	2,808.08	3,060.71	7,019.83
8	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss :						
	Remeasurements of defined benefit obligations	4.56	9.91	12.12	14.47	4.49	40.77
	Tax Impacts on above	(1.60)	(3.46)	(4.19)	(5.06)	(1.55)	(14.11)
	Total Other Comprehensive Income	2.96	6.45	7.93	9.41	2.94	26.66
9	Total comprehensive income (comprising profit after tax and other comprehensive income after tax for the period)	1,449.00	1,368.49	1,866.48	2,817.49	3,063.65	7,046.49
10	Paid-up equity share capital (Face Value of ₹ 5 each)	4,411.85	4,411.34	4,411.34	4,411.85	4,411.34	4,411.34
11	Earnings per share (Quarterly and Half yearly not annualised) :						
	Basic (₹)	1.64	1.54	2.11	3.18	3.47	7.96
	Diluted (₹)	1.64	1.54	2.11	3.18	3.47	7.95

M. Marchant



Statement of Assets and Liabilities:		(Rs. In Lacs)	
		As at 30.09.2018 (Unaudited)	As at 31.03.2018 (Audited)
ASSETS			
1	Non-current assets		
(a)	Property plant and equipment	25,153.35	24,293.76
(b)	Capital work-in-progress	1,311.01	966.39
(c)	Investment Property	345.97	348.98
(d)	Intangible assets	1,342.14	1,315.03
(e)	Intangible assets under development	881.78	858.15
(f)	Financial Assets		
	(i) Investment in subsidiaries/associates	3,336.05	561.06
	(ii) Investments	213.93	209.02
	(iii) Loans		
	(iv) Other non-current financial assets	1,363.55	672.66
(g)	Other non-current assets	874.29	1,257.39
	Total non-current assets	34,822.07	30,482.44
2	Current assets		
(a)	Inventories	7,619.61	6,855.09
(b)	Financial assets		
	(i) Investments	868.93	1,061.81
	(ii) Trade receivables	12,241.88	11,189.36
	(iii) Cash and cash equivalents	448.14	367.90
	(iv) Bank Balances other than (iii) above	4,344.89	1,668.60
	(v) Loans	46.80	15.76
	(vi) Other current financial assets	122.58	114.73
(c)	Other current assets	3,301.48	3,707.66
	Total current assets	28,994.31	24,980.91
	TOTAL ASSETS	63,816.38	55,463.35
EQUITY AND LIABILITIES			
EQUITY			
(a)	Equity share capital	4,411.85	4,411.34
(b)	Other equity	29,752.86	29,039.90
	Total equity	34,164.72	33,451.24
LIABILITIES			
1	Non-current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	12,083.38	7,911.58
	(ii) Other Financial Liabilities	533.96	497.55
(b)	Provisions	227.84	210.24
(c)	Government Grants	214.53	203.47
(d)	Deferred tax liabilities (Net)	1,856.06	1,572.01
	Total non-current liabilities	14,915.77	10,394.85
3	Current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	2,973.80	2,673.22
	(ii) Trade payables		
	a) total outstanding dues of micro enterprises and small enterprises	24.95	134.38
	b) total outstanding dues of creditors other than micro enterprises and small enterprises	4,139.90	4,186.18
	(iii) Other financial liabilities	6,717.07	3,784.60
(b)	Other current liabilities	711.48	805.99
(c)	Provisions	36.43	32.89
(d)	Current Tax Liabilities (Net)	132.25	
	Total Current Liabilities	14,735.89	11,617.26
	TOTAL EQUITY AND LIABILITIES	63,816.38	55,463.35


Munish



Notes:

- 1 The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 29th October, 2018. The Statutory auditors have conducted a limited review of the above Financial Results.
- 2 In line with the provisions of Ind AS 108 – Operating Segments and on the basis of review of operations being done by the management of the Company, the operations of the company falls under medical devices, which is considered to be the only reportable segment by the management.
- 3 The Company has invested Rs. 2,774.99 lacs in Poly Medisure B.V. Netherland whereby Poly Medisure B.V. Netherland has become wholly owned subsidiary of the Company. The said subsidiary company has further invested in Plan 1 Health SRL, Italy to the extent of 82% in its equity whereby Plan 1 Health SRL has become step subsidiary of the company.
- 4 Revenue for the period 01st April, 2017 to 30th June, 2017 were reported inclusive of excise duty. Accordingly, revenue for the half year ended 30th September, 2017 includes excise duty of Rs.126.10 lacs. Revenue for subsequent periods are net of Goods and Services Tax (GST).
- 5 During the quarter ended 30th September, 2018, the Company has allotted 10050 No. of Equity shares under Employees Stock option scheme 2015 at a face value of Rs. 5 each at an exercise price of Rs. 50 per share, however, listing of such shares and filing of necessary documents with ROC is under process.
- 6 The Company has opted to publish standalone financial results for the quarter and half year ended 30th September, 2018. The consolidated financial results shall be published for the quarter / year ending 31st March, 2019.
- 7 The standalone unaudited financial results of the Company for the quarter and half year ended 30th September, 2018 are also available on the Company's Website (www.polymedisure.com) and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com) in accordance with the provisions of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.
- 8 Previous period figures have been regrouped wherever necessary to conform to the current period classification.

Place : New Delhi
Date : 29.10.2018



Himanshu Bald

Himanshu Bald
Managing Director



DOOGAR & ASSOCIATES

Chartered Accountants

To Board of Directors
Poly Medicare Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020


We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicare Limited ("the company") for the quarter ended 30th September, 2018 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm Registration No. 000561N


M. S. Agarwal
Partner
Membership No. 86580



Place of signature: New Delhi
Date: 29th October 2018